Literature DB >> 566853

Fibrocystic breast disease in oral-contraceptive users. A histopathological evaluation of epithelial atypia.

V A LiVolsi, B V Stadel, J L Kelsey, T R Holford, C White.   

Abstract

Epidemiological studies show a lower frequency of fibrocystic breast disease among long-term users of oral contraceptives than among women who have never used them. Fibrocystic disease may be a precursor of breast cancer; yet the incidence of breast cancer does not appear to differ between pill-takers and nontakers. To resolve this conflict, we examined the problem from a histologic standpoint in 205 premenopausal women, and found that this decreased frequency applied only to fibrocystic disease in which epithelial atypia was minimal or absent. In women with marked atypia there was no significant difference in frequency among long-term users as compared to women who have never used oral contraceptives. These findings suggest that a spectrum of cystic disease exists and that the long-term use of oral contraceptives protects against the forms of fibrocystic disease that are not firmly associated with an increased risk of breast cancer, but not against the premalignant forms.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 566853     DOI: 10.1056/NEJM197808242990803

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  9 in total

1.  Investigation of a family suspected of being at high risk for cancer.

Authors:  J M Elwood; G M Crawford; M Werner
Journal:  Can Med Assoc J       Date:  1979-09-08       Impact factor: 8.262

Review 2.  Epidemiology and endocrinology of benign breast disease.

Authors:  D Y Wang; I S Fentiman
Journal:  Breast Cancer Res Treat       Date:  1985       Impact factor: 4.872

3.  The role of the obstetrician-gynecologist in the management of breast lesions.

Authors:  L R Weekes
Journal:  J Natl Med Assoc       Date:  1983-08       Impact factor: 1.798

4.  The morphologic effects of synthetic reproductive steroids on the mammary gland of rhesus monkeys. Mestranol, ethynerone, mestranol-ethynerone, chloroethynyl norgestrel-mestranol, and anagestone acetate-mestranol combinations.

Authors:  F A Tavassoli; H W Casey; H J Norris
Journal:  Am J Pathol       Date:  1988-05       Impact factor: 4.307

5.  Hormone prevention of mammary carcinogenesis by norethynodrel-mestranol.

Authors:  I H Russo; J Frederick; J Russo
Journal:  Breast Cancer Res Treat       Date:  1989-10       Impact factor: 4.872

6.  Risk factors for benign breast disease: a 30-year cohort study.

Authors:  T G Hislop; J M Elwood
Journal:  Can Med Assoc J       Date:  1981-02-01       Impact factor: 8.262

7.  Cigarette smoking and benign breast disease.

Authors:  G S Berkowitz; P F Canny; V A Vivolsi; M J Merino; T Z O'Connor; J L Kelsey
Journal:  J Epidemiol Community Health       Date:  1985-12       Impact factor: 3.710

8.  Risk factors for histologically confirmed benign breast tumors.

Authors:  M Rautalahti; D Albanes; J Haukka; J Virtamo
Journal:  Eur J Epidemiol       Date:  1994-06       Impact factor: 8.082

9.  Breast cancer and oral contraceptives: findings in Royal College of General Practitioners' study.

Authors: 
Journal:  Br Med J (Clin Res Ed)       Date:  1981-06-27
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.